Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) major shareholder Braden Michael Leonard acquired 135,546 shares of Adverum Biotechnologies stock in a transaction on Wednesday, July 17th. The shares were purchased at an average price of $7.75 per share, for a total transaction of $1,050,481.50. Following the completion of the purchase, the insider now directly owns 2,101,546 shares of the company’s stock, valued at $16,286,981.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Adverum Biotechnologies Stock Performance
Shares of ADVM opened at $8.17 on Friday. Adverum Biotechnologies, Inc. has a 52 week low of $6.38 and a 52 week high of $29.70. The stock has a market capitalization of $169.61 million, a price-to-earnings ratio of -0.80 and a beta of 1.07. The stock has a fifty day moving average of $7.66 and a 200-day moving average of $11.74.
Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.22). As a group, equities analysts forecast that Adverum Biotechnologies, Inc. will post -5.07 EPS for the current year.
Wall Street Analyst Weigh In
Get Our Latest Analysis on ADVM
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Apexium Financial LP bought a new stake in Adverum Biotechnologies during the 4th quarter worth approximately $45,000. Monaco Asset Management SAM lifted its holdings in shares of Adverum Biotechnologies by 33.8% during the fourth quarter. Monaco Asset Management SAM now owns 79,234 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 20,000 shares during the period. Twin Focus Capital Partners LLC bought a new stake in shares of Adverum Biotechnologies in the fourth quarter worth $75,000. Worth Venture Partners LLC grew its stake in shares of Adverum Biotechnologies by 136.5% in the fourth quarter. Worth Venture Partners LLC now owns 784,346 shares of the biotechnology company’s stock worth $590,000 after purchasing an additional 452,678 shares during the last quarter. Finally, Citigroup Inc. acquired a new stake in Adverum Biotechnologies in the third quarter valued at $715,000. Institutional investors and hedge funds own 48.17% of the company’s stock.
About Adverum Biotechnologies
Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.
Featured Stories
- Five stocks we like better than Adverum Biotechnologies
- How to Invest in Insurance Companies: A Guide
- Why This AI Stock is Rising Despite Tech Sell-Off
- How to Invest in Small Cap Stocks
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
- How to Calculate Inflation Rate
- MarketBeat Week in Review – 7/15 – 7/19
Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.